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ABSTRACT
The Epidermal Growth Factor Receptor (EGFR) is selectively expressed on the 
surface of numerous tumours, such as non-small cell lung, ovarian, colorectal and 
head and neck carcinomas. EGFR has therefore become a target for cancer therapy. 
Cetuximab is a chimeric human/mouse monoclonal antibody (mAb) that binds to 
EGFR, where it both inhibits signaling and induces cell death by antibody-dependent 
cell mediated cytotoxicity (ADCC). Cetuximab has been approved for clinical use in 
patients with head and neck squamous cell carcinoma (HNSCC) and colorectal cancer. 
However, only 15-20% patients benefit from this drug, thus new strategies to improve 
cetuximab efficiency are required. We aimed to develop a reliable and easy preclinical 
mouse model to evaluate the efficacy of EGFR-targeted antibodies and examine the 
immune mechanisms involved in tumour regression. We selected an anti-mouse EGFR 
mAb, 7A7, which has been reported to be “mouse cetuximab” and to exhibit similar 
properties to its human counterpart. Unfortunately, we were unable to reproduce 
previous results obtained with the 7A7 mAb. In our hands, 7A7 failed to recognize 
mouse EGFR, both in native and reducing conditions. Moreover, in vivo administration 
of 7A7 in an EGFR-expressing HPV38 tumour model did not have any impact on tumour 
regression or animal survival. We conclude that 7A7 does not recognize mouse EGFR 
and therefore cannot be used as the mouse equivalent of cetuximab use in humans. 
As a number of groups have spent effort and resources with similar issues we feel 
that publication is a responsible approach.
INTRODUCTION
The Epidermal Growth Factor Receptor (EGFR) 
is a 170-kDa protein that belongs to the ErbB family 
of receptor tyrosine kinases. It is composed of an 
extracellular ligand-binding domain, a single hydrophobic 
transmembrane region and an intracellular domain 
with intrinsic kinase activity that regulates many 
developmental, metabolic, and physiological processes 
[1, 2]. EGFR overexpression is associated with the 
development of several tumour malignancies, such as non-
small cell lung cancer, ovarian cancer, colorectal cancer 
and head and neck cancer [3]. Different EGFR signaling 
output pathways, such as the mitogen-activated protein 
kinases (MAPK) and the phosphoinositide 3-kinase/
Akt pathway, result in cell proliferation, migration 
and modulation of ion channels which may contribute 
to tumour invasion, metastasis and progression [4]. 
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Therefore, EGFR has been regarded as a central target for 
cancer therapy.
There are several EGFR-targeted drugs currently 
used in the clinic including therapeutic monoclonal 
antibodies (mAbs), which bind to the extracellular domain 
of EGFR, and small molecule inhibitors that target the 
EGFR signaling cascade, such as tyrosine kinase inhibitors 
(TKIs) [5]. Cetuximab is a chimeric human/mouse mAb 
that binds to the extracellular domain of EGFR and is 
approved by the FDA for the treatment of colorectal cancer 
with KRAS WT status and HNSCC [6]. Even though 
the majority of HNSCC patient tumours express EGFR 
(~98%), only approximately 15-20% of patients respond 
positively and benefit from this treatment [7, 8]. Previous 
studies have shown that cetuximab can trigger the innate 
or adaptive immune system, but the mechanisms are still 
unclear and need to be further studied [9–12].
In order to develop a reliable and easy preclinical 
mouse model to allow further analysis of immune system 
involvement in anti-EGFR mAb treatment, we selected an 
anti-mouse EGFR monoclonal antibody (7A7) to model 
cetuximab treatment. 7A7 was first produced and published 
in 2004 [13] where it was suggested to be a valuable 
antibody for EGFR-based therapeutic preclinical studies 
in mice. The original study showed 7A7 could successfully 
recognize mouse EGFR expression both in cells and tissue 
samples by fluorescence-activated cell sorting (FACS), 
Western blot (WB) and immunohistochemistry [13]. 7A7 
was also described to prolong survival and show anti-
metastatic effects in a D122 mouse tumour model [14]. 
These results suggested that 7A7 was a good candidate for 
EGFR targeted preclinical studies in mice, which led to its 
use in our study.
The objective of this study was to create an in 
vitro and in vivo pre-clinical platform with which to 
model cetuximab, using the monoclonal antibody 7A7. 
This would enable investigation of the impact that these 
therapies have on immune system activation and allow 
the assessment of underlying immune mechanisms of 
tumour rejection. Thus, in order to develop our mouse 
experiments, we tested the capacity of 7A7 to bind 
murine EGFR and to induce tumour regression. As a 
control, we parallel tested 7A7 Fc Silent, which contains 
key mutations that abrogate binding of Fc receptors, 
abolishing the antibody mediated cytotoxicity (ADCC) 
effector function of 7A7. Theoretically, both 7A7 and 7A7 
Fc Silent should recognize mouse EGFR and cross-react 
with human EGFR.
We demonstrate that neither 7A7 nor 7A7 Fc Silent 
specifically recognize either mouse or human EGFR. 7A7 
was unable to impact tumour growth in an EGFR-expressing 
HPV38 transplantable SCC tumour model. Our study is 
an exhaustive in vitro and in vivo characterization of the 
7A7 monoclonal antibody. We trust our results can allow 
researchers to make an informed decision when considering 
7A7 for EGFR-targeted preclinical studies in mice.
RESULTS
EGFR mRNA expression in human and murine 
cell lines
We selected 6 cell lines to analyze the specificity of 
7A7 to detect graded levels of mouse and human EGFR. 
We quantified EGFR mRNA by quantitative RT-PCR in 
2 human cell lines (A431 and MCF-7) and 4 murine cell 
lines (3T3-L1, NIH-3T3, HPV38, and TC-1). The human 
cell line A431 expressed more than one thousand-fold 
EGFR at the mRNA level when compared to MCF-7 cells 
(Figure 1A), in line with previously published data [15]. 
Based on a previous report describing the presence 
of Egfr expression in 3T3-L1 cells [16], we selected 3T3-
L1 cells as a comparator for Egfr expression in our cohort 
of murine cell lines. As shown in Figure 1B, Egfr mRNA 
levels varied widely among the 4 cell types tested. A SCC 
cell line that we developed in-house, HPV38, showed high 
Egfr mRNA expression similar to that of 3T3-L1 cells. In 
contrast, NIH-3T3 and TC-1 cells showed no significant 
evidence of Egfr mRNA expression, however, TC-1 cells 
are known to be tumourigenic when injected into mice (of 
relevance later) and hence TC-1 cells were selected for 
further study in subsequent experiments.
Characterizations of 7A7 binding to EGFR in 
human and murine cell lines
Having validated and identified EGFR positive 
and negative human and murine cell lines at an RNA 
level, we evaluated the capacity of 7A7 mAb to detect 
EGFR protein by SDS-PAGE Western blot (SDS WB). 
Immunoblotting of human A431 and murine 3T3-L1 and 
HPV38 protein extracts with the polyclonal goat anti-
mouse antibody “AF1280” showed an ~170 KDa band 
which corresponded with the predicted size of EGFR 
(Figure 2A) [17]. A similar band was not detected for 
TC-1 cells, as expected. However, in our study, we did not 
observe specific binding of 7A7 or 7A7 Fc Silent mAbs 
to EGFR by Western blot (Figure 2B; β-tubulin loading 
controls shown in Figures 2C and 2D). Both 7A7 and 7A7 
Fc Silent antibodies bound numerous bands which did not 
consistently correspond to the molecular weight of EGFR 
or to the bands seen for AF1280 antibody (see EGFR 
quantifications in Figures 2A and 2B, and the comparative 
values following quantification of a non-specific band in 
Figure 2B). These results indicate that 7A7 and 7A7 Fc 
Silent mAbs fail to selectively detect both human and 
mouse EGFR proteins.
To determine whether 7A7 could still bind EGFR in 
its native conformation, EGFR localisation was analysed 
by immunofluorescence and flow cytometry using the 
human cell line A431 and three murine cell lines 3T3-
L1, HPV38, and TC-1. Cetuximab, a human EGFR-
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specific antibody, immuno-stained EGFR on the plasma 
membrane in A431 cells (red arrow), as confirmed by its 
co-localisation with the membrane marker wheat germ 
agglutinin (WGA, green) (Figure 3A, green arrow) [18]. 
The cell lines 3T3-L1 and HPV38 express EGFR. Murine 
EGFR was not detected by the human-specific cetuximab, 
as expected. The AF1280 antibody detected low levels 
of EGFR on the plasma membrane of both 3T3-L1 and 
HPV38 cells (Figure 3B), and high levels of EGFR on the 
plasma membrane of A431 cells, consistent with levels of 
mRNA observed in Figure 1. Also consistent with Figure 
1, TC-1 cells showed no staining with AF1280 antibody 
(Figure 3B). Staining of 7A7 and 7A7 Fc Silent were 
similar between cell lines. Unexpectedly, both 7A7 and 
7A7 Fc Silent showed cytoplasmic staining in A431 
cells, 3T3-L1 cells, and HPV38 cells, and both plasma 
membrane and cytoplasmic staining in TC-1 cells, which 
do not express EGFR (Figure 3C, 3D). The presence of 
7A7 and 7A7 Fc Silent immunostaining in the cytoplasm 
of both EGFR positive and negative cell lines again 
suggests non-specific binding by 7A7.
We also used flow cytometry to examine the capacity 
of 7A7 to bind to the EGFR. The surface expression 
of EGFR in A431 cells was successfully detected by 
both cetuximab and AF1280 antibody (Figure 4A). 
Interestingly, staining was also detected on the surface 
of A431 cells by 7A7 and 7A7 Fc Silent (Figure 4A). 
The AF1280 antibody detected EGFR on the surface of 
3T3-L1 and HPV38, however, while 7A7 weakly stained 
3T3-L1 cells, 7A7 Fc Silent did not, and neither antibody 
stained the surface of HPV38 cells (Figure 4A). Similar to 
our observations by immunofluorescence, only when the 
three murine cell lines were permeabilised to investigate 
intracellular protein production did 7A7 and 7A7 Fc Silent 
antibodies produce consistent staining (Figure 4B). Taken 
together, these data suggest that 7A7 and 7A7 Fc Silent 
bind to an unknown intracellular protein(s) which do not 
correspond to human nor murine EGFR.
EGFR immunostaining in tumour samples
Next, we wanted to assess EGFR expression and 
localisation in our preclinical mouse models. We harvested 
HPV38 and TC-1 tumours growing in mice, and examined 
the expression of EGFR in paraffin-embedded sections by 
immunofluorescence (Figure 5). We demonstrated that 
the AF1280 antibody could successfully detect EGFR on 
the plasma membrane of HPV38 tumour sections but not 
in TC-1 derived tumours (Figure 5A–5B). In contrast, 
7A7 and 7A7 Fc Silent antibodies failed to detect EGFR 
protein expression on the same tumour samples.
In vivo administration of 7A7 mAb did not 
affect tumour growth in subcutaneous TC-1 and 
HPV38 tumours
Our experiments indicate that 7A7 does not detect 
mouse EGFR in vitro. To investigate the ability of 7A7 
to target EGFR and modulate tumour growth in vivo, we 
used 7A7 to treat mice with established HPV38 or TC-1 
tumours. Mice were challenged with viable HPV38 or 
TC-1 cells, and after tumours reached 0.2-0.3 cm3 in size, 
the mice were treated every three days with either 7A7 
or PBS (or 7A7 Fc Silent – HPV38 tumours only). No 
Figure 1: EGFR mRNA expression in vitro in 2 human cell lines (A431 and MCF-7) and 4 murine cell lines (3T3-L1, 
HPV38, NIH-3T3, and TC-1). (A) A431 expressed more than 1 thousand-fold EGFR compared to MCF-7 cells. (B) 3T3-L1 and 
HPV38 expressed detectable levels of Egfr. NIH-3T3 and TC-1 did not express detectable levels of Egfr. The p-value was determined using 
(A) unpaired student’s t-test or (B) one-way ANOVA analysis, followed by a post-hoc Tukey’s multiple comparisons test (data compared 
with TC-1), n = 3 (*p < 0.05, ****p < 0.0001, n.s: not significant). Data shown is representative of one experiment of three with similar results.
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significant differences in TC-1 growth (Figure 6A) nor 
survival (Figure 6B) were observed following treatment, 
as predicted. Similarly, in the HPV38 tumour model, no 
significant differences in tumour growth (Figure 6C) nor 
survival (Figure 6D) were observed between treatments. 
Cumulatively, these results required us to reconsider 7A7 
as a model for mAb therapy targeted against EGFR in 
mice.
DISCUSSION
EGFR is considered to be an important target 
for multiple cancer therapies [19, 20]. Currently, two 
different types of EGFR targeted drugs are used in the 
clinic, therapeutic mAbs which can block the extracellular 
ligand-binding domain and induce ADCC, and small 
molecule inhibitors targeting the EGFR signaling cascade 
[21]. The vast majority of commercially-available EGFR-
targeted antibodies are specific for human EGFR. Thus, 
preclinical data is normally derived from human tumour 
xenograft models in immune-suppressed mice [22]. 
However, to fully understand the characteristics of these 
EGFR targeted drugs the role of the immune system needs 
to be considered. This could be assessed in preclinical 
mouse tumour models in the context of an active immune 
system. Therefore, there is a necessity for proper anti-
mouse EGFR antibody models to be developed in mice to 
enable these preclinical studies.
7A7, an anti-mouse EGFR IgG1 mAb, was first 
published by Garrido et al. in 2004 [13]. The authors 
demonstrated 7A7 could recognise mouse EGFR and 
was cross-reactive with the human EGFR. Additionally, 
they found that 7A7 could inhibit EGF-induced EGFR 
signaling in D122 tumour cells, triggering tumour 
regression in a T-cell dependent manner [14, 23]. Thus, 
it was suggested that 7A7 was similar to cetuximab and 
an ideal anti-mouse EGFR mAb candidate for preclinical 
studies. We therefore chose to pursue this antibody as a 
model to establish pre-clinical studies.
This is the first unbiased study of 7A7 and 7A7 Fc 
Silent mAbs and their potential anti-tumour capacity. The 
in vitro specificity of 7A7 mAb and 7A7 Fc Silent, which 
are produced by different hybridomas, was assessed by 
WB, IF and FACS in different human and mouse cell 
lines. We found that neither 7A7 nor 7A7 Fc Silent could 
detect human nor murine EGFR by SDS-WB, however 
both antibodies were able to bind to some unknown 
proteins inside the cell as determined by SDS-WB, IF 
Figure 2: 7A7 and 7A7 Fc Silent do not detect EGFR expression by Western blot. Protein was extracted from A431, MCF-7, 
3T3-L1, NIH-3T3, HPV38, and TC-1 cells, and immunoblotted for EGFR (A–B) and β-tubulin (C–D). (A) AF1280; (B) 7A7 and 7A7 Fc 
Silent; (C) and (D) β-tubulin internal loading controls for (A) and (B) respectively. EGFR was detected as a ~ 170kDa band by AF1280 
(as shown by arrow). Numbers at the bottom of each lane in (A) and (B) represent quantification of each lane normalised to corresponding 
β-tubulin measurements and relative to the highest resulting ratio on the respective blots. * = position of non-specific band used as a 
comparator for EGFR-specificity. E/β-tub; EGFR/β-tubulin, N/β-tub; non-specific band/β-tubulin.
Oncotarget12254www.impactjournals.com/oncotarget
and FACS techniques. The specificity of the 7A7 mAb 
to bind EGFR expressed by in vivo tumours was studied 
in HPV38 and TC-1 (control) tumour samples. However, 
in contrast to staining with our positive control AF1280 
antibody, 7A7 failed to detect EGFR expression on 
EGFR+ HPV38 tumour sections by IF. This is unlikely to 
be due to batch issues as 7A7 mAb and 7A7 Fc Silent are 
produced by different hybridomas and colleagues at other 
institutes discussed similar issues with 7A7 (personal 
communications).
Lastly, we characterized the anti-tumour capacity 
of 7A7 in in vivo TC-1 and HPV38 tumour models. We 
followed the dose and dosing schedule outlined in the 
original papers describing the in vivo use of 7A7 [14, 23]. 
In contrast to our data, Garrido et al. showed that 7A7 
could detect mouse EGFR successfully on the TC-1 cell 
line in vitro. Interestingly however, the TC-1 tumour 
was reported to be insensitive to 7A7 treatment, with 
the escape mechanisms not identified [24]. A second cell 
line, 3LL-D122, was also reported to express EGFR, but 
was responsive to 7A7 treatment [24], suggesting that 
EGFR expression levels in these two murine cell lines 
were not directly indicative of treatment response to 
7A7. In our hands, we could not demonstrate that TC-1 
tumour cells express EGFR, but we also found that 7A7-
treated mice bearing TC-1 tumours failed to show tumour 
regression or a halt in growth when compared to PBS-
injected mice. However, the same was true for HPV38 
tumours, which we were able to confirm express EGFR by 
multiple methods. In conclusion, contrary to the findings 
of previously published studies [13, 14, 22, 25–27], our 
results did not find any evidence to support that 7A7 is 
able to recognise mouse or human EGFR on either cell 
lines or tumour tissue.
The reason of this discrepancy is unclear. However, 
aside from the laboratory that first reported 7A7, we note 
that there are no other publications in the literature that 
have used this mAb. Ideally, a direct comparison should 
be made using the 3LL-D122 cell line, which is a highly 
metastatic clone of 3LL, however this cell line is not 
widely available and we have been unable to obtain it. 
Upon receipt of 7A7 and 7A7 Fc Silent we ascertained 
that there was antibody in the tubes by measuring the 
protein concentration and running a sample of the antibody 
on an SDS-PAGE gel and subsequently performing 
Coomassie staining; both the heavy and light chain of the 
antibodies appeared intact and undegraded. We can’t know 
whether the batch of 7A7 used in the study was faulty/
Figure 3: 7A7 and 7A7 Fc Silent do not detect EGFR expression by immunofluorescence. Four cell lines, A431, 3T3-L1, 
HPV38 and TC-1 were used to assess the binding of cetuximab (A), AF1280 (B), 7A7 (C) and 7A7 Fc Silent (D) antibodies as described 
in Materials and Methods. Red staining: Alexa Fluor 594-conjugated secondary antibodies, Blue staining: DAPI (nucleus), Green staining: 
plasma membrane as indicated by wheat germ agglutinin (WGA-FITC). Cmab; Cetuximab. Scale bar is 20 µm.
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Figure 4: 7A7 and 7A7 Fc Silent do not detect EGFR expression by flow cytometry. Human (A431) and mouse (3T3-L1, 
HPV38 and TC-1) cell lines were stained for cell surface EGFR (A) or intracellular EGFR (B) with cetuximab, AF1280, 7A7 and 7A7 Fc 
Silent antibodies (blue peaks) or isotype control antibodies (red peaks) as described in Materials and Methods.
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damaged, however we have compared 7A7 with 7A7 Fc-
silent, which is produced by a different hybridoma and 
is therefore a “different batch”. 7A7 Fc-silent has been 
modified at the Fc antibody region so that it will not bind 
to Fc receptors and induce antibody-dependent cellular 
cytotoxicity, however it should still bind to the EGFR by 
its antigen-binding domains and this should be detectable. 
However, we could not demonstrate EGFR binding by 
7A7 OR 7A7 Fc silent. Unfortunately, there is not an 
alternative supplier of 7A7 and the original authors have 
yet to respond to our requests for a sample of 7A7.  A 
further experiment that could be performed to assess the 
specificity of 7A7 is to transfect murine Egfr into a cell 
line as a positive control for Egfr expression. However, 
since our study shows that 7A7 recognised many bands 
in both Egfr positive and Egfr negative cell lines and was 
mislocalised by immunofluorescence, it seems likely that 
non-specific binding is occurring. Based on our data we 
conclude that 7A7 does not detect mouse EGFR and it is 




C57BL/6 mice were purchased from the Animal 
Resources Centre (Perth, Australia). HPV38E6E7 
FVB x Rag1 KO mice were bred and maintained at the 
Translational Research Institute Biological Research 
Figure 5: 7A7 and 7A7 Fc Silent do not detect EGFR expression in HPV38 tumour tissue by immunofluorescence. 
EGFR expression in formalin fixed paraffin-embedded samples from HPV38 (A) and TC-1 (control; B) tumour tissues. Sections were 
immunostained with 3 primary antibodies (7A7, 7A7 Fc Silent and AF1280) and Alexa Fluor 594-conjugated anti-mouse or anti-goat 
secondary antibodies (red). Secondary only (Alexa594-conjugated goat anti-mouse IgG1 or Alexa594-conjugated donkey anti-goat IgG1) 
served as negative controls. Nuclei were stained using DAPI (blue). Scale bar is 20 µm.
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Facility (Brisbane, Australia). All mice were 6–12 week 
females housed under specific pathogen-free conditions. 
Animal procedures were approved by the University of 
Queensland Animal Ethics Committee.
Cell lines
The HPV38 SCC cell line was established in our 
laboratory following the UV-induction of an SCC tumour 
in an HPV38E6E7-FVB transgenic mouse [28]. HPV38 
cells were cultured in modified Ham’s F12 media (Thermo 
Fisher Scientific, Waltham, MA, USA). Modified Ham’s 
F12 media: 25% Dulbecco’s Modified Eagle’s Medium 
(DMEM)/high glucose (Thermo Fisher Scientific), 5% 
fetal bovine serum (FBS, Thermo Fisher Scientific), 5µg/
mL insulin (Sigma-Aldrich, Castle Hill, NSW, Australia), 
0.4 µg/mL hydrocortisone (Sigma-Aldrich), 10 ng/mL 
human recombinant epidermal growth factor (Invitrogen, 
Carlsbad, CA), 8.4 ng/mL Cholera toxin from Vibrio 
cholera (Sigma-Aldrich), 24 µg/mL adenine (Sigma-
Aldrich) and 1X penicillin/streptomycin/glutamine (Life 
Technologies, Carlsbad, CA). TC-1 cells were maintained 
in RPMI1640 (Life Technologies), containing 20% FBS. 
A431, MCF-7, NIH-3T3, and 3T3-L1 cell lines were 
maintained in DMEM containing 10% FBS. All cells were 
grown at 37°C in 5% CO2.
Quantitative real time PCR (q-PCR)
Total RNA isolated from cells was subjected to 
cDNA synthesis and q-PCR using iQ SYBR-Green 
Supermix as per manufacturer’s instructions (Invitrogen). 
cDNA reverse reactions were incubated under the 
following conditions: 65°C 5 mins, 4°C 1 min, 25°C 
5mins, 50°C 60 mins, 70°C 15 mins, 4°C∞.The mRNA 
levels were normalized to that of the housekeeping 
gene, hypoxanthine guanine phosphoribosyltransferase 
(HPRT) based on the threshold cycle (Ct) of each 
sample in RT q-PCR. Relative levels of mRNA 
expression were calculated from ΔCt where ΔCt = 
Figure 6: 7A7 does not affect tumour growth in vivo. Established TC-1 (A–B) or HPV38 (C–D) tumours were treated with PBS 
(i.v.) or 56ug of 7A7 (i.v.) or 7A7 Fc Silent (i.v.) every three days. (A, C) Tumour growth curves, and (B, D) survival curves. (A, B) n = 4-6 
mice/group; (C–D) n = 4 mice/group. Data shown represent two independent experiments. (A-D) No statistical differences between groups.
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(test mRNA Ct- HPRT Ct). The forward and reverse 
primers (5′–3′) used were as follows: mEgfr forward: 
TCTTCAAGGATGTGAAGTGTG; mEgfr reverse: 
TGTACGCTTTCGAACAATGT; hEGFR forward: 
GCCAAGGCACGAGTAACAAGC; hEGFR reverse: 
AGGGCAATGAGGACATAACC. 
Western blot analysis
Cell lysates were prepared in RIPA buffer (1% 
Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS in 
10mM Tris-HCl pH7.4) with protease and phosphatase 
inhibitor set (CatLog# 539134, Calbiochem, Merck 
KGaA, Darmstadt, Germany). Protein concentrations 
were determined using the PierceTM BCA protein assay kit 
(Thermo Fisher Scientific) according to the manufacturer’s 
instructions. Cell extracts were applied to 8% SDS-
PAGE gels and transferred to polyvinylidinedifluoride 
membranes (PVDF; Sigma-Aldrich). PVDF membranes 
were blocked with 2% BSA in PBS and incubated with 
7A7 (mouse, Absolute Antibody, Oxford, UK), 7A7 Fc 
Silent (mouse, Absolute Antibody), anti-mouse EGFR 
“AF1280” (polyclonal goat antibody, R&D Systems, 
New South Wales, Australia) or β-tubulin (clone 2-28-33, 
Invitrogen) primary antibodies and anti-mouse or anti-goat 
HRP secondary antibodies (Invitrogen). Membranes were 
incubated with Chemiluminescent Substrate (Bio-rad, 
Gladesville, Australia) and imaged using the ChemiDoc 
XRS+ System with Image Lab™ software (Bio-rad).
Immunofluorescence
Cells were seeded onto coverslips in 6-well 
plates and grown in culture medium for 24h. Cells were 
incubated with wheat germ agglutinin (WGA-FITC) (Life 
Technologies), then fixed with 4% paraformaldehyde for 
30mins, washed with PBS and permeabilised with 0.1% 
Triton-X100 (Sigma-Aldrich) for 10 mins. Coverslips 
were blocked with 2% BSA/PBS and then incubated 
with 7A7, 7A7 Fc Silent, cetuximab (Merck) or AF1280 
primary anti-EGFR antibodies diluted in 2% BSA/PBS for 
60 mins at room temperature. After washing with PBS, 
cells were incubated with Alexa Fluor 594-conjugated 
anti-mouse, anti-human or anti-goat IgG antibodies (Life 
Technologies), respectively. Samples were imaged using 
the Zeiss 510 meta confocal microscope (Zeiss, Lonsdale, 
Australia) and images were processed using Image J and 
Adobe illustrator.
Immunofluorescence of paraffin-embedded 
sections
EGFR expression was analysed in formalin-fixed 
paraffin embedded tumour sections as described below. 
Sections were deparaffinised in xylene (twice for 5 minutes) 
and rehydrated with alcohol (twice in 100% alcohol for 
5 minutes, and then in 90%, 80%, 70%, 50%, 30% for 1 
minute each). Antigen retrieval was performed using 20ul/
ml proteinase K solution for 10 min at 37°C. Sections were 
then washed with PBS and blocked with 10% mouse serum 
in PBS for 30 minutes. Sections were then incubated with 
either 7A7, 7A7 Fc Silent, cetuximab or AF1280 antibody 
overnight at 4°C. After washing with PBS, sections were 
incubated with Alexa-Fluor-594 conjugated anti-mouse, 
anti-human or anti-goat secondary antibodies (Life 
Technologies) respectively. Samples were imaged using 
the Zeiss 510 meta confocal microscope (Zeiss, Lonsdale, 
Australia) and images were processed using Image J.
Flow cytometry 
Cells were prepared for flow cytometry by washing 
with PBS and then FACs buffer (2% FBS in PBS). Cell 
suspensions (1x106cells) were stained with 7A7, 7A7 Fc 
Silent, cetuximab or AF1280 antibodies, and incubated 
with Alexa 488-conjugated-anti-mouse, anti-human 
or anti-goat secondary antibodies (Life Technologies) 
respectively. For intracellular staining, fixation and 
permeabilisation of cells was performed using a Fix & 
Perm cell permeabilisation kit (eBioscience, Thermo 
Fisher Scientific) according to the manufacturer’s 
instructions. Samples were acquired on a Fortessa X20 
flow cytometer (BD Bioscience, New Jersey, USA) and 
data analyzed using Flow Jo 10.0 software (Treestar, San 
Carios, CA, USA).
Tumour transplantation and antibody treatment
1x106 TC-1 cells or 1x106 HPV38 cells were injected 
subcutaneously into C57BL/6 mice or HPV38E6E7 x Rag1 
KO mice respectively, in 100ul of PBS solution. Once 
tumours had grown to 0.2-0.3cm3 the animals received 
PBS (i.v.), 7A7 (56 µg, i.v.), or 7A7 Fc Silent (56 µg, i.v.) 
every three days to experimental endpoint as per respective 
groups. Tumour growth was recorded three times per week. 
Statistical analysis
All statistical analysis was carried out using GraphPad 
Prism version 6.02 or 7.03 (GraphPad Software, San 
Diego, CA, USA). Statistical analysis of RT-PCR data was 
performed using an unpaired student’s t-test or a one-way 
ANOVA with post-hoc Tukey’s multiple comparisons test, 
and statistical analysis of mouse survival data was performed 
using a Log-rank (Mantel-Cox) test. A p value of p < 0.05 (*) 
was considered significant. p < 0.0001 (****) is also indicated.
ACKNOWLEDGMENTS
We thank the staff at the TRI Flow cytometry 
core and TRI biological Research Facility for providing 
excellent service.
Oncotarget12259www.impactjournals.com/oncotarget
CONFLICTS OF INTEREST 
The authors declare no conflicts of interest.
FUNDING
This work was supported by a Dr Jian Zhou 
Memorial scholarship to X.E, a University of Queensland 
Postdoctoral Fellowship to J.L.C, Cancer Council 
Queensland Grant (#1041390), the Queensland Head and 
Neck Cancer Centre and the Princess Alexandra Hospital 
Research Foundation Grant (#2016030) to F.S, and a 
Perpetual Trustees Fellowship to J.W.W. 
REFERENCES
 1. Gazdar AF. Activating and resistance mutations of EGFR 
in non-small-cell lung cancer: role in clinical response to 
EGFR tyrosine kinase inhibitors. Oncogene. 2009; 28:S24–
31, https://doi.org/10.1038/onc.2009.198.
 2. Carpenter CD, Ingraham HA, Cochet C, Walton GM, Lazar 
CS, Sowadski JM, Rosenfeld MG, Gill GN. Structural 
analysis of the transmembrane domain of the epidermal 
growth factor receptor. J Biol Chem. 1991; 266:5750–5755.
 3. Nicholson RI, Gee JM, Harper ME. EGFR and cancer 
prognosis. Eur J Cancer. 2001; 37:S9–15.
 4. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino 
M, Maiello MR, Carotenuto A, De Feo G, Caponigro F, 
Salomon DS. Epidermal growth factor receptor (EGFR) 
signaling in cancer. Gene. 2006; 366:2–16. https://doi.
org/10.1016/j.gene.2005.10.018.
 5. Johnston JB, Navaratnam S, Pitz MW, Maniate JM, 
Wiechec E, Baust H, Gingerich J, Skliris GP, Murphy LC, 
Los M. Targeting the EGFR pathway for cancer therapy. 
Curr Med Chem. 2006; 13:3483–3492.
 6. Franken MD, Koopman M, van Oijen MG. Cetuximab 
as First-line Treatment for Metastatic Colorectal Cancer: 
Caution With Interpretation of Cost-Effectiveness Results 
Toward Medical Decision Making. Am J Clin Oncol. 2016; 
39:214. https://doi.org/10.1097/COC.0000000000000253.
 7. Bardelli A, Siena S. Molecular mechanisms of resistance 
to cetuximab and panitumumab in colorectal cancer. J 
Clin Oncol. 2010; 28:1254–1261. https://doi.org/10.1200/
JCO.2009.24.6116.
 8. Bardelli A, Janne PA. The road to resistance: EGFR 
mutation and cetuximab. Nat Med. 2012; 18:199–200.
https://doi.org/10.1038/nm.2646.
 9. Bibeau F, Lopez-Crapez E, Di Fiore F, Thezenas S, Ychou M, 
Blanchard F, Lamy A, Penault-Llorca F, Frébourg T, Michel P, 
Sabourin JC, Boissière-Michot F. Impact of Fc{gamma}RIIa-
Fc{gamma}RIIIa polymorphisms and KRAS mutations on the 
clinical outcome of patients with metastatic colorectal cancer 
treated with cetuximab plus irinotecan. J Clin Oncol. 2009; 
27:1122–1129, https://doi.org/10.1200/JCO.2008.18.0463.
10. Kubach J, Hubo M, Amendt C, Stroh C, Jonuleit H. IgG1 
anti-epidermal growth factor receptor antibodies induce 
CD8-dependent antitumor activity. Int J Cancer. 2015; 
136:821–830. https://doi.org/10.1002/ijc.29037).
11. Srivastava RM, Trivedi S, Concha-Benavente F, Gibson 
SP, Reeder C, Ferrone S, Ferris RL. CD137 Stimulation 
Enhances Cetuximab-Induced Natural Killer: Dendritic 
Cell Priming of Antitumor T-Cell Immunity in Patients with 
Head and Neck Cancer. Clin Cancer Res. 2017; 23:707–16. 
https://doi.org/10.1158/1078-0432.CCR-16-0879.
12. Chen S, Li X, Chen R, Yin M, Zheng Q. Cetuximab 
intensifies the ADCC activity of adoptive NK cells in a 
nude mouse colorectal cancer xenograft model. Oncol Lett. 
2016; 12:1868–1876. https://doi.org/10.3892/ol.2016.4835.
13. Garrido G, Sanchez B, Rodriguez HM, Lorenzano P, 
Alonso D, Fernandez LE. 7A7 MAb: a new tool for 
the pre-clinical evaluation of EGFR-based therapies. 
Hybrid Hybridomics. 2004; 23:168–75. https://doi.
org/10.1089/1536859041224280.
14. Garrido G, Rabasa A, Garrido C, López A, Chao L, García-
Lora AM, Garrido F, Fernández LE, Sánchez B. Preclinical 
modeling of EGFR-specific antibody resistance: oncogenic 
and immune-associated escape mechanisms. Oncogene. 
2014; 33:3129–3139.https://doi.org/10.1038/onc.2013.288.
15. Weihua Z, Tsan R, Huang WC, Wu Q, Chiu CH, Fidler IJ, 
Hung MC. Survival of cancer cells is maintained by EGFR 
independent of its kinase activity. Cancer Cell. 2008; 
13:385–393. https://doi.org/10.1016/j.ccr.2008.03.015.
16. Pagano E, Calvo JC. ErbB2 and EGFR are downmodulated 
during the differentiation of 3T3-L1 preadipocytes. J Cell 
Biochem. 2003; 90:561–572. https://doi.org/10.1002/
jcb.10647.
17. Siegelin MD, Borczuk AC. Epidermal growth factor 
receptor mutations in lung adenocarcinoma. Lab 
Invest. 2014; 94:129–137. https://doi.org/10.1038/
labinvest.2013.147.
18. Selvestrel F, Moret F, Segat D, Woodhams JH, Fracasso G, 
Echevarria IM, Baù L, Rastrelli F, Compagnin C, Reddi E, 
Fedeli C, Papini E, Tavano R, et al. Targeted delivery of 
photosensitizers: efficacy and selectivity issues revealed by 
multifunctional ORMOSIL nanovectors in cellular systems. 
Nanoscale. 2013; 5:6106–6116. https://doi.org/10.1039/
c3nr00402c.
19. Bethune G, Bethune D, Ridgway N, Xu Z. Epidermal 
growth factor receptor (EGFR) in lung cancer: an overview 
and update. J Thorac Dis. 2010; 2:48–51.
20. Juergens RA, Bratman SV, Tsao MS, Laurie SA, Sara 
Kuruvilla M, Razak AR, Hansen AR. Biology and patterns 
of response to EGFR-inhibition in squamous cell cancers of 
the lung and head & neck. Cancer Treat Rev. 2017; 54:43–
57. https://doi.org/10.1016/j.ctrv.2017.01.003.
21. Arteaga CL. Epidermal growth factor receptor dependence 
in human tumors: more than just expression? Oncologist. 
2002; 7:31–39.
Oncotarget12260www.impactjournals.com/oncotarget
22. Talavera A, Mackenzie J, Garrido G, Friemann R, 
López-Requena A, Moreno E, Krengel U. Structure of 
the Fab fragment of the anti-murine EGFR antibody 
7A7 and exploration of its receptor binding site. Mol 
Immunol. 2011; 48:1578–1585. https://doi.org/10.1016/j.
molimm.2011.03.016.
23. Garrido G, Lorenzano P, Sánchez B, Beausoleil I, Alonso 
DF, Pérez R, Fernández LE. T cells are crucial for the anti-
metastatic effect of anti-epidermal growth factor receptor 
antibodies. Cancer Immunol Immunother. 2007; 56:1701–
1710. https://doi.org/10.1007/s00262-007-0313-4.
24. Garrido G, Sánchez B, Pérez R, Fernández LE. The anti-
tumor activity of the 7A7 antibody, specific to murine 
EGFR, is independent of target expression levels in 
immunocompetent mice. Biotecnol Apl. 2007; 24:26–32.
25. Rabasa Capote A, González JE, Rodríguez-Vera L, López A, 
Sánchez Ramírez B, Garrido Hidalgo G. Pharmacokinetics 
and Biodistribution Study of 7A7 Anti-Mouse Epidermal 
Growth Factor Receptor Monoclonal Antibody and Its 
F(ab’)(2) Fragment in an Immunocompetent Mouse 
Model. ISRN Pharmacol. 2012; 2012:417515. https://doi.
org/10.5402/2012/417515.
26. Garrido G, Rabasa A, Sánchez B, López MV, Blanco R, 
López A, Hernández DR, Pérez R, Fernández LE. Induction 
of immunogenic apoptosis by blockade of epidermal 
growth factor receptor activation with a specific antibody. 
J Immunol. 2011; 187:4954–4966. https://doi.org/10.4049/
jimmunol.1003477.
27. Gonzalez JE, Leon M, Hernandez I, Garrido G, Casaco 
A. Effect of the maternofetal and milk transfer of the anti-
epidermal growth factor receptor monoclonal antibody 
7A7 in mice. Placenta.2011; 32:470–474. https://doi.
org/10.1016/j.placenta.2011.03.011.
28. Viarisio D, Mueller-Decker K, Kloz U, Aengeneyndt B, 
Kopp-Schneider A, Gröne HJ, Gheit T, Flechtenmacher C, 
Gissmann L, Tommasino M. E6 and E7 from beta HPV38 
cooperate with ultraviolet light in the development of 
actinic keratosis-like lesions and squamous cell carcinoma 
in mice. PLoS Pathog. 2011; 7:e1002125. https://doi.
org/10.1371/journal.ppat.1002125.
